Honeywell announced last week the opening of a plant in Baton Rouge that is the company’s first large-scale manufacturing site for Solstice Air, a near-zero global-warming-potential (GWP) medical propellant for use in respiratory inhalers.
Solstice Air is a non-flammable, near-zero GWP, non-ozone-depleting, volatile organic compound (VOC)-exempt propellant in clinical development for pressurized metered-dose inhalers. AstraZeneca, a global leader in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), is working to incorporate Honeywell’s Solstice Air technology. Read the entire announcement.
